SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes
5 references·0 citing·21 second hop
Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes (2019)Illuminating an Invisible Epidemic: A Sys…High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes (2018)High-Deductible Insurance and…Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment (2018)Breast Cancer Diagnosis and T…The cost of multiple sclerosis drugs in the US and the pharmaceutical industry (2015)The cost of multiple sclerosi…Impact of a High-deductible Health Plan on Outpatient Visits and Associated Diagnostic Tests (2013)Impact of a High-deductible H…Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Projections of the Cost of Ca…Race/Ethnicity, Gender, and Monitoring Socioeconomic Gradients in Health: A Comparison of Area-Based Socioeconomic Measures—The Public Health Disparities Geocoding Project (2003)Evaluation of the Effect of a Consumer‐Driven Health Plan on Medical Care Expenditures and Utilization (2004)Healthcare spending and preventive care in high-deductible and consumer-directed health plans. (2011)Prevalence and reasons for delaying and foregoing necessary care by the presence and type of disability among working-age adults (2016)Health Care Financing Review (1980)Cost of Care for Elderly Cancer Patients in the United States (2008)American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care (2009)Delivering affordable cancer care in high-income countries (2011)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Medical Care Costs Associated with Cancer Survivorship in the United States (2020)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases (2017)Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA (2017)Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. (1992)Financial Toxicity of Cancer Care: It’s Time to Intervene (2015)Vulnerable And Less Vulnerable Women In High-Deductible Health Plans Experienced Delayed Breast Cancer Care (2019)Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions (2022)Unmet Health Needs of Uninsured Adults in the United States (2000)
this work references cited by second hop

References

  • 2011Projections of the Cost of Cancer Care in the United States: 2010-20202,726 cited
  • 2015The cost of multiple sclerosis drugs in the US and the pharmaceutical industry261 cited
  • 2018Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment108 cited
  • 2013Impact of a High-deductible Health Plan on Outpatient Visits and Associated Diagnostic Tests53 cited
  • 2018High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes53 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work